Compare AbbVie Inc (ABBV) vs Conagra Brands Inc (CAG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Conagra Brands Inc — how do they compare? AbbVie Inc trades at $253.8 (market cap $449.91B), while Conagra Brands Inc trades at $13.86 (market cap $6.71B). The key difference: AbbVie Inc is far larger — about 67.1× Conagra Brands Inc's market cap, and Conagra Brands Inc pays the higher dividend (9.98%). Which is the better fit depends on your goals.
| ABBV | CAG | |
|---|---|---|
Market Cap | $449.91B | $6.71B |
Sector | Health | Consumer Staples |
52-Week High | $261.07 | $20.65 |
52-Week Low | $184.85 | $12.58 |
Enterprise Value | $513.38B | $13.99B |
Dividend Yield | 2.72% | 9.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
Conagra Brands (CAG) trades at $14.035, down 2.06% on the day, with mixed technical signals and a neutral overall stance. The stock shows modest valuation metrics with a P/E of 10.06 and P/B of 0.81, but faces profitability challenges with a negative net income margin of -0.39%. Recent earnings have been inconsistent, missing estimates in two of the last three quarters. A high dividend yield of approximately 10% is under scrutiny amid concerns over debt levels and slowing growth under new leadership, with the company set to report Q4 earnings on July 15, 2026.
The outlook for CAG is cautious, with potential upside from defensive positioning and dividend income, but significant risks from earnings volatility, high leverage, and dividend sustainability concerns. Investor sentiment is divided, with analysts predominantly neutral, reflecting uncertainty around the company's ability to navigate operational headwinds and debt management effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →
